SARS-CoV-2 Nirmatrelvir Resistance-A Concern for Immunocompromised Populations?

JAMA Netw Open. 2024 Sep 3;7(9):e2435439. doi: 10.1001/jamanetworkopen.2024.35439.

Authors

Zhuo Zhou¹, Peng Hong^{2

3}

Affiliations

¹ State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China.
² Division of Research and Development, VA New York Harbor Healthcare System, Brooklyn.
³ Sun Yat-sen University School of Medicine, Shenzhen, China.

PMID: 39320895
DOI: 10.1001/jamanetworkopen.2024.35439

No abstract available

MeSH terms

Adenosine Monophosphate / analogs & derivatives
Adenosine Monophosphate / therapeutic use
Antiviral Agents / therapeutic use
COVID-19 Drug Treatment
COVID-19* / immunology
Drug Resistance, Viral
Humans
Immunocompromised Host*
SARS-CoV-2* / immunology

Substances

Antiviral Agents
Adenosine Monophosphate